These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21296778)

  • 1. Incidence, risk factors, and consequences of new-onset atrial fibrillation following epicardial ablation for ventricular tachycardia.
    Mahapatra S; LaPar DJ; Bhamidipati CM; McDaniel G; Kamath S; Bunch TJ; Ailawadi G
    Europace; 2011 Apr; 13(4):548-54. PubMed ID: 21296778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients treated with catheter ablation for ventricular tachycardia after an ICD shock have lower long-term rates of death and heart failure hospitalization than do patients treated with medical management only.
    Bunch TJ; Weiss JP; Crandall BG; Day JD; May HT; Bair TL; Osborn JS; Mallender C; Fischer A; Brunner KJ; Mahapatra S
    Heart Rhythm; 2014 Apr; 11(4):533-40. PubMed ID: 24333283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations.
    Gasparini M; Kloppe A; Lunati M; Anselme F; Landolina M; Martinez-Ferrer JB; Proclemer A; Morani G; Biffi M; Ricci R; Rordorf R; Mangoni L; Manotta L; Grammatico A; Leyva F; Boriani G
    Eur J Heart Fail; 2018 Oct; 20(10):1472-1481. PubMed ID: 29251799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of steroid therapy on the incidence of pericarditis and atrial fibrillation after percutaneous epicardial mapping and ablation for ventricular tachycardia.
    Dyrda K; Piers SR; van Huls van Taxis CF; Schalij MJ; Zeppenfeld K
    Circ Arrhythm Electrophysiol; 2014 Aug; 7(4):671-6. PubMed ID: 24970295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.
    AbdelWahab A; Sapp J
    Curr Cardiol Rep; 2017 Sep; 19(11):105. PubMed ID: 28900864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrial arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and ventricular tachycardia.
    Chu AF; Zado E; Marchlinski FE
    Am J Cardiol; 2010 Sep; 106(5):720-2. PubMed ID: 20723652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ablation of atrial fibrillation in Brugada syndrome patients with an implantable cardioverter defibrillator to prevent inappropriate shocks resulting from rapid atrial fibrillation.
    Sairaku A; Yoshida Y; Nakano Y; Kihara Y
    Int J Cardiol; 2013 Oct; 168(6):5273-6. PubMed ID: 23988302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance and clinical characteristics of atrial fibrillation post epicardial access.
    Sugrue A; Killu AM; Hodge DO; McLeod CJ; Munger TM; Mulpuru SK; Packer DL; Kapa S; Asirvatham SJ; Friedman PA
    J Interv Card Electrophysiol; 2017 Mar; 48(2):141-146. PubMed ID: 27943113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success.
    Schreiber D; Rostock T; Fröhlich M; Sultan A; Servatius H; Hoffmann BA; Lüker J; Berner I; Schäffer B; Wegscheider K; Lezius S; Willems S; Steven D
    Circ Arrhythm Electrophysiol; 2015 Apr; 8(2):308-17. PubMed ID: 25744570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of catheter ablation for paroxysmal atrial fibrillation in patients with Brugada syndrome and an implantable cardioverter-defibrillator to prevent inappropriate shock therapy.
    Kitamura T; Fukamizu S; Kawamura I; Hojo R; Aoyama Y; Komiyama K; Nishizaki M; Hiraoka M; Sakurada H
    Heart Rhythm; 2016 Jul; 13(7):1455-9. PubMed ID: 26961302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of catheter ablation in patients with implantable cardioverter defibrillators and multiple inappropriate ICD therapies due to atrial fibrillation and type I atrial flutter.
    Korte T; Niehaus M; Meyer O; Tebbenjohanns J
    Pacing Clin Electrophysiol; 2001 Jul; 24(7):1061-6. PubMed ID: 11475820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of atrial fibrillation with rapid ventricular rates and device programming on shocks in 106,513 ICD and CRT-D patients.
    Fischer A; Ousdigian KT; Johnson JW; Gillberg JM; Wilkoff BL
    Heart Rhythm; 2012 Jan; 9(1):24-31. PubMed ID: 21835150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of single atrial fibrillation catheter ablation on implantable cardioverter defibrillator therapies in patients with ischaemic and non-ischaemic cardiomyopathies.
    Kosiuk J; Nedios S; Darma A; Rolf S; Richter S; Arya A; Piorkowski C; Gaspar T; Sommer P; Husser D; Hindricks G; Bollmann A
    Europace; 2014 Sep; 16(9):1322-6. PubMed ID: 24532559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catheter ablation of atrial tachyarrhythmias causing inappropriate implantable cardioverter-defibrillator shocks.
    Miyazaki S; Taniguchi H; Kusa S; Komatsu Y; Ichihara N; Takagi T; Iwasawa J; Kuroi A; Nakamura H; Hachiya H; Hirao K; Iesaka Y
    Europace; 2015 Feb; 17(2):289-94. PubMed ID: 25061229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and relevance of nonreentrant monomorphic ventricular tachycardia in patients with frequent implantable cardioverter defibrillator interventions.
    Fiek M; Remp T; Fleckenstein M; Pohl T; Deiss M; Reithmann C
    J Interv Card Electrophysiol; 2015 Mar; 42(2):151-60. PubMed ID: 25620151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in amiodarone efficacy in relation to ejection fraction and basal rhythm in patients with implantable cardioverter defibrillators.
    Watanabe T; Inoue K; Kashiwase K; Mine T; Hirooka K; Shutta R; Mizuno H; Okuyama Y; Sakata Y; Nanto S;
    J Electrocardiol; 2018; 51(6):1111-1115. PubMed ID: 30497740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subxiphoid Hybrid Epicardial-Endocardial Atrial Fibrillation Ablation and LAA Ligation: Initial Sub-X Hybrid MAZE Registry Results.
    Ellis CR; Badhwar N; Tschopp D; Danter M; Jackson GG; Kerendi F; Walters T; Fang Q; Deuse T; Beygui R; Lee RJ
    JACC Clin Electrophysiol; 2020 Dec; 6(13):1603-1615. PubMed ID: 33334437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of atrial arrhythmias in patients with ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy.
    Zado ES; Garg L; Tschabrunn C; Santangeli P; Hyman M; Kumareswaran R; Arkles J; Marchlinski FE
    Heart Rhythm; 2024 Feb; 21(2):133-140. PubMed ID: 37956774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Catheter Ablation in Arrhythmogenic Right Ventricular Cardiomyopathy Without Background Implantable Cardioverter Defibrillator Therapy: A Multicenter International Ventricular Tachycardia Registry.
    Santangeli P; Tung R; Xue Y; Chung FP; Lin YJ; Di Biase L; Zhan X; Lin CY; Wei W; Mohanty S; Burkhardt DJ; Zado ES; Callans DJ; Marchlinski FE; Wu S; Chen SA; Natale A
    JACC Clin Electrophysiol; 2019 Jan; 5(1):55-65. PubMed ID: 30678787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of early radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation complicated with amiodarone-induced thyrotoxicosis.
    Wang M; Cai S; Sun L; Zhao Q; Feng W
    Cardiol J; 2016; 23(4):416-21. PubMed ID: 27296156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.